NUVEI CORPORATION ANNOUNCES ANNUAL MEETING RESULTS
Get Alerts NVEI Hot Sheet
Join SI Premium – FREE
1. Election of Directors
The eight (8) nominees for directors proposed by management of the Company were elected by a majority of the votes cast by the shareholders present or represented by proxy at the Meeting. The votes cast for each nominee were as follows:
Nominees | Percentage of Votes For | Percentage of Votes Against |
99.90 % | 0.10 % | |
Timothy A Dent | 97.84 % | 2.16 % |
97.84 % | 2.16 % | |
97.46 % | 2.54 % | |
97.48 % | 2.52 % | |
99.58 % | 0.42 % | |
99.93 % | 0.07 % | |
99.97 % | 0.03 % |
2. Appointment of Auditors
PricewaterhouseCoopers LLP were appointed as auditors of the Company by a majority of the votes cast by the shareholders present or represented by proxy at the Meeting. The votes cast were as follows:
Percentage of Votes For | Percentage of Votes Withheld |
99.87 % | 0.13 % |
Final voting results on all matters voted on at the Meeting will be filed under the Company's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
About Nuvei
Nuvei (Nasdaq: NVEI) (TSX: NVEI) is the Canadian fintech company accelerating the business of clients around the world. Nuvei's modular, flexible and scalable technology allows leading companies to accept next-gen payments, offer all payout options and benefit from card issuing, banking, risk and fraud management services. Connecting businesses to their customers in more than 200 markets, with local acquiring in 50 markets, 150 currencies and 700 alternative payment methods, Nuvei provides the technology and insights for customers and partners to succeed locally and globally with one integration.
For more information, visit www.nuvei.com.
NVEI-IR
Contact:
Investors
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvei-corporation-announces-annual-meeting-results-302155479.html
SOURCE Nuvei
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
- Wave Life Sciences starts Phase 2a obesity trial for WVE-007 drug
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share